ReviewTransactions of the American Clinical and Climatological Association2003
The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.
Review in Transactions of the American Clinical and Climatological Association, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 76 citations in OpenAlex.
- The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.Pharmacological reviews · 2022Review
- Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors.Exploration of targeted anti-tumor therapy · 2021Article
- The Charming World of the Extracellular Matrix: A Dynamic and Protective Network of the Intestinal Wall.Frontiers in medicine · 2021Review
- Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.Cancer metastasis reviews · 2020Review
- HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior.Cancer science · 2020Article
- Cellular and Molecular Mediators of Intestinal Fibrosis.Journal of Crohn's & colitis · 2017Review
- Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals.Targeted oncology · 2015Review
- Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2013Article
- Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.International journal of molecular sciences · 2012Review
- Cellular and molecular mechanisms of intestinal fibrosis.World journal of gastroenterology · 2012Article
- Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.PloS one · 2011Article
- Molecular evidence for differences in endometrium in severe versus mild endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2011Article
- In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor.Journal of translational medicine · 2010Article
- Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.The Journal of steroid biochemistry and molecular biology · 2010Article
- The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.Molecular and cellular biology · 2009Article
- The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.Molecular endocrinology (Baltimore, Md.) · 2007Article
- ErbB receptors in fetal endothelium--a potential linkage point for inflammation-associated neonatal disorders.Cytokine · 2006Article
- Discovery and characterization of inhibitors of human palmitoyl acyltransferases.Molecular cancer therapeutics · 2006Article
- A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens.Journal of immune based therapies and vaccines · 2006Article
- ErbB receptor negative regulatory mechanisms: implications in cancer.Journal of mammary gland biology and neoplasia · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EGF Receptor (EGFR), the first transmembrane receptor tyrosine kinase cloned and sequenced, and its closely related family members HER2, HER3, and HER4, play myriad roles in mammalian growth and development. Receptor activation involves ligand binding to separate receptors followed by formation of active dimers. These receptors can signal as homodimers or they can subtly alter signaling output by heterodimerizing with other family members. Adding complexity, these receptors with varying specificity bind at least 10 ligands from two ligand families, the EGF and neuregulin/heregulin families. This signaling system's impact on human neoplasia is underscored by the following: i.) EGFR is overexpressed or activated by autocrine or paracrine growth factor loops in at least 50% of epithelial malignancies; ii.) HER2 is amplified and dramatically overexpressed in approximately 20%-25% or breast cancers; iii) HER3 and HER4 are variably expressed in breast and other cancers. Overexpression and/or activation of EGFR, HER2 and HER3 has been correlated with poor tumor prognosis; antibody and small molecule inhibitors of their activity are being tested as therapy in cancer patients. However, the signaling complexity engendered by four interacting receptors and ten ligands makes it difficult to definitively measure receptor signaling output in human tumors and even makes mechanistic studies of the family's role in normal physiology and neoplastic transformation a challenge. In spite of the literature's emphasis on growth control, activation by some EGF receptor family member ligands can produce tumor cell differentiation, characterized by growth cessation and differentiation gene product synthesis. The present work delineates a role for HER4 in breast cancer cell differentiation and demonstrates that HER4 is both necessary and sufficient to produce an anti-proliferative signal. These
Indexed as
Identifiers
12813928PMC2194503W214420200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.